Last reviewed · How we verify

FutureChem — Portfolio Competitive Intelligence Brief

FutureChem pipeline: 0 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 1 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
[F-18]Florastamin [F-18]Florastamin phase 3 statin HMG-CoA reductase Cardiovascular

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. HTA Co., Ltd. · 1 shared drug class
  2. Merck Sharp & Dohme LLC · 1 shared drug class
  3. VA Office of Research and Development · 1 shared drug class
  4. Zhejiang Hisun Pharmaceutical Co. Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for FutureChem:

Cite this brief

Drug Landscape (2026). FutureChem — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/futurechem. Accessed 2026-05-14.

Related